AnaptysBio Inc.

About AnaptysBio Inc.

AnaptysBio is a clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases by delivering innovative immunology therapeutics. Their mission is to transform patient health through best-in-class antibodies designed to dampen inflammatory responses and restore immune balance, guided by core values of transparency, accountability, and humility.

Products & Services

Rosnilimab:An investigational therapeutic in Phase 2 clinical trials for autoimmune and inflammatory diseases.

ANB033:A CD122 antagonist under development for immunology-related conditions, with a virtual investor event scheduled for October 14, 2025.

ANB101:A therapeutic candidate in the pipeline for addressing immune-related disorders.

Partnerships:Collaborations with other entities to develop and advance immunology therapeutics.

Specialties

Immunology therapeutics Autoimmune diseases Inflammatory diseases Antibody development Immune cell modulation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Offering T: - FT: Equity Offering	A: 100000000 MR: - FA: approximately $100 million FAN: 100000000	D: 2024-08-14 FD: 2024-08-14	7 investors
2	RT: Royalty Financing T: - FT: Royalty Financing	A: 50000000 MR: - FA: 50 million FAN: 50000000	D: 2024-05-09 FD: 2024-05-09	1 investors

Equity Offering Latest

2024-08-14

$100.0M

7 investors (Pro only)

Royalty Financing 2024-05-09

$50.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Ben Stone

Chief Business Officer

B

Beth Mueller

Senior Vice President, Human Resources

D

Daniel Faga

President & CEO

D

David McKeon

Senior Vice President, Controller

D

Dennis Mulroy

Chief Financial Officer

D

Doug Rich

Senior Vice President, CMC

View 21 more team members with Pro

Unlock Full Team Directory

Recent News

AnaptysBio Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised